Novartis | NVS - Assets


Novartis reported $118.53B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bausch Health Companies USD 24.5B 1.87B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Drreddys Laboratories INR 579.35B 573.08B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
Perrigo USD 7.98B 551.9M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Phibro Animal Health USD 1.45B 39.56M Mar/2026
Prestige Brands USD 3.49B 430K Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sanofi EUR 128.02B 1.22B Mar/2026
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026
Zoetis USD 15.15B 313M Mar/2026